ClinicalTrials.gg
RecruitingNCT07395778Updated Feb 9, 2026

Nasojejunal Feeding Versus Oral Feeding Following Endoscopic Drainage of Walled Off Pancreatic Necrosis

An interventional study of endoscopic ultrasonography guided cystogastrostomy in Walled Off Pancreatic Necrosis, Acute Pancreatitis (AP) and Endoscopic Ultrasound-Guided Drainage, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Recruiting at 1 site in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Pancreatitis with a site in India — 7 open to participants now, 7 under way, 2 of them phase 3. Pancreatitis · India.

Planned enrollment
10th of 13
50 · median 140
Started
2025
with 1 other
No phase
6 of 18
2 open now
Registered
17th of 18
by date
Lead sponsor
6 of 18
Post Graduate Institute of Medical Education and Research, Chandigarh

Among the 18 studies in Pancreatitis with a site in India, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 with no phase, and was the 17th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

7 of the 18 studies in Pancreatitis with a site in India are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Pancreatitis with a site in India, or all of them as a file.
02

Study summary

The goal of this randomized control trial is to assess whether nasojejunal feed is better than oral nutrition in patients who are undergoing endoscopic cystogastrostomy of walled off necrosis following acute pancreatitis. It will also try to answer, the incidence of infections and feed tolerance.

The main question it tries to answer is

  1. whether nasojejunl feed is better than oral feed in patients undergoing endoscopic cystogastrostomy in walled off necrosis following acute pancreatitis
  2. How much infections they develop, whether they are able to tolerate the feed, weight gain and reintervention rates in each group
03

Conditions studied

  • Walled Off Pancreatic Necrosis
  • Acute Pancreatitis (AP)
  • Endoscopic Ultrasound-Guided Drainage

Browse trials for

Keywords

  • Cystogastrostomy, Walled off pancreatic necrosis, nutrition
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of acute pancreatitis (AP) with 18-75 years of age
  2. Patients with symptomatic WON requiring EUS guided transluminal drainage
  3. Provision of written

Exclusion criteria

Exclusion Criteria:

  1. Patients with collection not amenable for EUS guided drainage (distance of WON >1 cm from the gastrointestinal lumen)
  2. Known or state
  3. Previous upper gastrointestinal(GI) surgery interfering with absorption
  4. Active GI bleeding
  5. GI obstruction, ileus or persistent vomiting
  6. Patients moribund to undergo endoscopic procedure (Glasgow coma scale \<8 or patients on ventilatory support)
  7. Patients with irreversible coagulopathy like \<50,000/mm3 and/or >1.5
  8. Pregnant or lactating female
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Nasojejunal feeding arm

    Procedure: endoscopic ultrasonography guided cystogastrostomy

  • Active comparator
    Oral feeding

    Procedure: endoscopic ultrasonography guided cystogastrostomy

Interventions

  • Procedureendoscopic ultrasonography guided cystogastrostomy

    Nasojejunal tube will be placed post EUS-CG or oral diet would be started after randomization

06

What researchers measure

Primary outcomes

  1. Nutritional failure

    To compare the rate of nutritional failure at Day 14 between Nasojejunal and oral feeding post endoscopic transmural drainage of WON

    Time frame: 14 days

Secondary outcomes

  1. Infection and new onset organ failure

    To compare infection rates, need for antibiotic escalation and new onset organ failure

    Time frame: 14 days

  2. Re-intervention needs

    To compare the need for re-intervention and hospital stay duration in either of the group

    Time frame: 14 days

  3. Change in weight

    To compare patient weight

    Time frame: 14 days

  4. Inflammatory markers

    To compare change in inflammatory markers (CRP, Serum Albumin)

    Time frame: 14 days

07

Study locations

1 of 1 sites recruiting
  • Post Graduate Institute of Medical Education and Research (PGIMER)
    Chandigarh, 160012, India
    Recruiting
    • Surinder Singh Rana, DM · Contactdrsurindersrana@gmail.com · +919560113930
    • Saurabh Kumar Singh, MD · Principal investigator
    • Surinder Singh Rana, DM · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After 1 year

Access criteria: Who wants to publish individual data meta-analysis

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 14 months is below that.

Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Feb 9, 2026
StartActual
Oct 18, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 2027
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395778
Responsible party
Saurabh Kumar Singh (Senior Resident, Department of Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Feb 9, 2026
Start date
Oct 18, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 9, 2026

Study contacts

Saurabh Kumar Singh
Contact
drsaurabhkrsingh@gmail.com
+919560113930
Surender Singh Rana, Professor
principal investigator · Post Graduate Institute of Medical Education and Research, Chandigarh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion